Maureen Loftus, president of IBT, said: “IBT Laboratories was one of the first laboratories to develop a commercial pneumococcal assay to measure the concentration of antibodies produced in response to the pneumococcal vaccines -today, one of the most-widely prescribed tests used to determine why a patient has recurrent infections.
“Our new avidity test now lets the clinician assess the effectiveness of those antibodies. Together, these pneumococcal tests provide more insight into the strengths and weaknesses of a patient’s immune system.”